Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc...for $1.3 billion in 2004, began its second life when the big pharma spun out the firm and lead asset ETC-1002 in 2008. (See BioWorld Today, May 2, 2008.) It raised $22.8 million in a Series A round and recently added $33 million in a preferred stock deal...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for

Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Kite Pharma Inc., of Los Angeles, said it closed a $20 million private placement of shares of its Series A preferred stock...Receptos will use the proceeds to support clinical work in multiple sclerosis, inflammatory bowel disease and allergic/immune-mediate disorders. (See BioWorld Today

Eisai Inc., of Woodcliff Lake, N.J., said antiepileptic drug Fycompa (perampanel) showed a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy, according to two new analyses of early clinical experience

The study, dubbed Gammaglobulin Alzheimer's Partnership, was conducted in collaboration with the Alzheimer's Disease Cooperative Study, a clinical trial consortium supported by the National Institute on Aging

Astellas Pharma Inc., of Tokyo, and Drais Pharmaceuticals Inc., of Bridgewater, N.J., will repeat for the third time a spinout maneuver that has been successful with two other programs in the past...In April 2012, Astellas transferred ownership of ASP3291, a melanocortin receptor agonist for ulcerative colitis, to Telsar Pharma Inc., with a $14 million investment by InterWest and Sutter Hill, to begin Phase IIa testing. (See BioWorld Today, Nov. 1, 2013.) And in June 2012, Drais partnered with

shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection...The firm also has programs in two big pharma partnerships...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.

Critics of the firm, too, have pointed to the lack of a big pharma partner to expand Qsymia's reach. (See BioWorld Today, Oct. 23, 2012.) Lief said Belviq already has picked up some momentum...The drug was included in a recent diabetes management report from the American Association of Clinical Endocrinologists

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...That's the sweet spot for a number of pharma companies...ERYtech Pharma SA, of Lyon, France, has had its prospectus accepted for a proposed initial public offering on the NYSE Euronext exchange in Paris

clinical trials, for SMD and dry age-related macular degeneration (dry AMD...BHR Pharma LLC, of Herndon, Va., said the 1,000th patient has been enrolled in its SyNAPSe clinical trial, a global Phase III study evaluating the effectiveness of its intravenous progesterone infusion agent, BHR-100, to treat severe traumatic brain injury (TBI...BHR Pharma is sponsoring SyNAPSe with the intent to bring the first-ever approved TBI treatment to market

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes...Eyevensys, of Paris, received an equity investment from the Boehringer Ingelheim Venture Fund, the venture arm of Ingelheim, Germany-based Boehringer Ingelheim GmbH, and said the big pharma's head of nonclinical R&D, Michel Pairet, was appointed to its board

The study was carried out to explore previous clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases showing a 67 percent rate of bone scan response and other clinical signs of effect...MEI Pharma Inc., of San Diego, presented data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a preclinical in vivo model of recurrent epithelial ovarian cancer

Last month, it inked a deal with AbbVie, of Chicago, giving the big pharma firm an option to RPC4046 following the Phase II proof-of-concept trial in EoE...MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologic malignancies, and for

The financing included both new and existing institutional investors, including Essex Woodlands, NovaQuest Pharma Opportunities Fund, Delphi Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Bio*One Capital, Pac-Link Ventures and Palo Alto Fund...The latest round is expected to support ongoing clinical development of lead candidate, LiRIS (lidocaine releasing intravesical system), in development for patients with interstitial cystitis.

A big pharma partner could ease some of the pressure on Vivus...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

Another $406 million could come in the form of clinical, regulatory and commercial milestones, and Enanta would be eligible for tiered, double-digit royalties and a U.S...and London-based GW Pharma plc, which is seeking a Nasdaq listing and a capital raise. (See BioWorld Today, March 11, 2013, March 12, 2013, and March 20, 2013.) In other financings news...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate

The study design calls for the collection of 5,250 clinical endpoints, and Merck remains blinded to the actual results of the analysis and to other safety and efficacy data

Inc., of Whitehouse Station, N.J., said researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of Tredaptive (extended-release niacin/laropiprant) during the late-breaking clinical trial session at the American College of Cardiology 62nd Annual Scientific Session in San Francisco...Findings were presented during the late-breaking clinical trial session

Janssen and partner Bayer AG, of Leverkusen, Germany, will enroll patients into five global clinical trials, which will involve a total of 28,850 patients

Zealand Pharma A/S, of Copenhagen, Denmark, disclosed in a pipeline update that it plans to advance danegaptide into a single site clinical efficacy study to further profile the peptide drug in cardio protection